Bayer’s Rally Faces a Two-Week Reckoning: A Missouri Settlement and Q2 Cash Flow Results Will Determine if the Supreme Court Win Sticks
01.07.2026 - 03:32:51 | boerse-global.de
The US Supreme Court handed Bayer a decisive victory on June 25, ruling 7-2 that federal law preempts state-level failure-to-warn claims against glyphosate products where the EPA has conducted a safety review. The decision effectively kills tens of thousands of lawsuits that argued Monsanto’s herbicide lacked adequate cancer warnings. Investors cheered, sending Bayer’s stock to €48.28 — within 3.3% of its 52-week high and up 21% in just seven days. The shares have nearly doubled from a year ago, gaining 88%.
But the euphoria masks a precarious reality. The ruling does not shield Bayer from design-defect or negligence claims — the categories that produced the largest verdicts against the company. And it does not guarantee approval of the $7.25 billion class settlement that Bayer hopes will cap its glyphosate liabilities once and for all.
That settlement now heads to a make-or-break hearing on July 9 in a St. Louis court. Plaintiff attorneys have already voiced strong objections to the terms. If the judge rejects the deal or demands major revisions, the legal containment strategy that drove the rally collapses. If approved, it would complement the Supreme Court decision by providing a mechanism to resolve both current and future claims — at least for those who opt in.
Overbought and Overstretched
Technicians are sounding alarms. The relative strength index stands at 80, deep in overbought territory. The stock trades 26.5% above its 50-day moving average and more than 31% above its 200-day average — gaps that historically precede consolidation. With annualized 30-day volatility at 59.5%, the price action is clearly febrile.
Should investors sell immediately? Or is it worth buying Bayer?
The fundamental story is equally mixed. Bayer’s pharmaceutical pipeline is gathering momentum: Nubeqa grew 57% in the first quarter, Kerendia 84%. The group posted revenue of €13.4 billion, up 4.1% on a currency-adjusted basis, and EBITDA before special items rose 9% to €4.5 billion. The blood thinner Asundexian, which failed in an earlier atrial fibrillation trial, has rebounded with a stroke-prevention study showing a 26% risk reduction and no excess bleeding. The FDA and China granted it accelerated review in May, and the European Medicines Agency began evaluating the application in June. Analysts see a potential US approval by late 2026 or early 2027.
Yet none of that progress is visible in the cash flow. Free cash flow in the first quarter was negative €2.32 billion, and Bayer’s finance chief, Wolfgang Nickl, has guided for full-year cash outflows of up to €2.5 billion — driven almost entirely by litigation payments. The company expects to spend roughly €5 billion on legal matters this year alone. Net debt stood at €32.5 billion at the end of March, with no near-term relief in sight.
The Pipeline That Has to Deliver
Bayer has chalked up three new drug approvals, two label expansions, and six positive late-stage trial readouts across 2025 and 2026. A menopause treatment, a heart drug, and a targeted lung cancer therapy are opening new markets. Kerendia received an expedited FDA review for a label expansion. Management’s long-term target calls for a return to mid-single-digit pharma growth from 2027 and an operating margin of around 30% by 2030.
But the patent cliff on Xarelto — whose sales slid by a third to $2.6 billion last year — demands replacement revenue fast. Asundexian is the most promising candidate, but its earlier failure means any future setback would deal a harsh blow.
What Comes Next
Two events will define the summer. The July 9 hearing in Missouri will determine whether the $7.25 billion settlement receives final approval. If it stalls, a central pillar of Bayer’s containment strategy vanishes, and the stock’s recent gains look fragile.
Bayer at a turning point? This analysis reveals what investors need to know now.
On August 7, Bayer releases second-quarter results, including the customary analyst call with segment detail. The market will scrutinize whether management raises its full-year guidance — stable currency-adjusted revenue and mid-single-digit EBITDA growth — in light of the Supreme Court win. More importantly, any sign that free cash flow is improving would provide the fundamental ballast the rally currently lacks.
Bayer has won a legal battle, not the war. The Supreme Court ruling clears a major obstacle, but the balance sheet remains strapped and the design-defect lawsuits — the costliest category — are untouched. The stock is pricing in a near-perfect outcome. Over the next month, investors will learn whether that optimism is justified or whether the rally has simply front-run a settlement that hasn’t yet closed.
Ad
Bayer Stock: New Analysis - 1 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
